our vision
our mission
awards
BOARD - members
MagBiosense, Inc. has put together a great team to achieve its mission.
Dr. Amos Danielli
Founder and CEO, founded MagBiosense in 2013 to commercialize the technology he invented and developed since 2004 in Tel Aviv University, Israel. Dr. Danielli, PhD, is a third-time entrepreneur with 15 years of experience in executive R&D positions and in the development of multidisciplinary systems in the medical device, communications and solar energy industries.
Dr. Paul Olivo
Is a board certified internist and physician scientist with extensive experience in biotechnology and in vitro diagnostics. He holds multiple patents in the field of diagnostic virology and has developed multiple FDA-cleared diagnostic tests.His technology was instrumental in building Diagnostic Hybrids, Inc. to $40M in sales before it was acquired by Quidel Corporation (San Diego, CA) for $130M in 2010. Dr. Olivo was also President and CSO of Apath, LLC, a St. Louis start-up company that held key hepatitis C IP. Under Dr. Olivo’s leadership, Apath generated over $20M in licensing income and secured $12M in federal grants to support its antiviral drug discovery program. Most recently, Dr. Olivo was Senior Medical Director at Quidel. Presently, he is a senior entrepreneur-in-residence at Biogenerator and a Director at Common Place Holdings.
Dr. Heschel Raskas
Professor of Pathology and Microbiology and the former CEO of Raskas Foods, which became one of the leading innovative store brand companies in the United States. He currently serves on the Advisory Boards of several privately held St. Louis companies. Since the founding of Innovate St Louis, he has served on its Board and Chairs the Innovate St. Louis Venture Mentoring Service. In addition he has held leadership positions in local, national and international Jewish philanthropic organizations.
James Howard
Mr. Howard is the President & CEO of Readout Health, a St. Louis-based breath diagnostic company supporting chronic diseases. Prior to his current role, he was co-founder and CEO of surgical AR platform company SentiAR, raising initial capital, including a $2.2m NIH grant to commercialize the Washington University technology for interventional electrophysiology procedures. His 27-year career has been spent in commercial leadership roles with exits with medical device leader CareFusion (BD), digital health startup Pharmacy OneSource (Wolters Kluwer Health), and Marsam Pharmaceuticals (Schein/Watson). Jim is an investor in MagBiosense and board member since 2015. He is an active mentor in the local healthcare startup ecosystem.
Roy Oron
Roy has focused on angel and early stage investments in leading edge enterprises in the technology, biotechnology, pharma and life sciences sectors in Israel. Currently, Roy is an advisor to StageOne Ventures and is a co-founder of SEPL Pharma. Roy hold a bachelor’s degree in economics and Statistics as well as MBA from the Hebrew university of Jerusalem and B.Sc. in Biotechnology from Tel Aviv University. Roy serves as a Board Member in the International Board of the Weizmann Institute of Science. The Weizmann Institute of Science is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. Roy serves as the founder and Managing Partner of ITI – Venture Capital Partners, an investment firm he co-founded with the support of Investec Bank to invest with entrepreneurs in extraordinary Israeli technology companies. ITI’s strategic focus is on building intellectual and corporate competencies in Israel and maintaining the operating nucleus in the country throughout the phases of maturation.
COMPANY SITES
St. Louis
Israel
